REL-1017 (dextromethadone) in Other Indications

The activation of NMDA receptors has potential clinical effect in many diseases. The company is performing preclinical work in Rett Syndrome, Ophthamology, mitochondrial diseases and ALS. Rett Syndrome is an orphan indication affecting approximately 15,000 people in the U.S.

REL-1017 Development Pipeline

Indication 2018 2019
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Rett Syndrome PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
Ophthalmology Formulation & PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
Mitochondrial Diseases / ALS PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
*Depends on preclinical results, FDA feedback and available capital resources.
Clinical
Preclinical